person · Reporting owner
Beneski Benjamin Machinas
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | SVP, Chief Technical Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,338 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Sale · Disposed 2,867 · Balance 195,338 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 20:47 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 2,867 | $2.50 | $7,167.50 |
DisclosureSEC source: 0002057918-26-000007 · wk-form4_1775162856.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,338 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:06 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 4,835 | $2.47 | $11,942.45 |
DisclosureSEC source: 0001737287-26-000015 · wk-form4_1773864406.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,205 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:42 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 7,132 | $2.60 | $18,543.20 |
DisclosureSEC source: 0002057918-26-000003 · wk-form4_1772664133.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,040 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:20 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantRestricted Stock Unit · Derivative | 105,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-26-000011 · wk-form4_1770243619.xml · derivative · entry 3 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,720 Underlying: Common Stock · 105,720 shares Expires not disclosed F4 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:20 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 373,757 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001737287-26-000011 · wk-form4_1770243619.xml · derivative · entry 2 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,757 Underlying: Common Stock · 373,757 shares Expires 2036-02-02 F3 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:20 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 7,549 | $1.73 | $13,059.77 |
DisclosureSEC source: 0001737287-26-000011 · wk-form4_1770243619.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,172 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:09 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 786 | $1.22 | $958.92 |
DisclosureSEC source: 0001737287-25-000094 · wk-form4_1763586562.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,721 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.22 to $1.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:28 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | SaleCommon Stock | 5,488 | $1.98 | $10,838.80 |
DisclosureSEC source: 0001737287-25-000040 · wk-form4_1742333277.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,507 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at the single price point of $1.975. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 21:11 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to buy) · Derivative | 112,339 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001737287-25-000026 · wk-form4_1741209067.xml · derivative · entry 2 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,339 Underlying: Common Stock · 112,339 shares Expires 2035-03-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 21:11 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 31,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001737287-25-000026 · wk-form4_1741209067.xml · nonDerivative · entry 1 Beneski Benjamin Machinas · CIK 0002057918 · SVP, Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,995 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.